Cite
HARVARD Citation
Sakellari, I. et al. (2019). Brentuximab vedotin and anti‐PD1 treatment optimize survival in chemo‐refractory Hodgkin lymphoma patients: Real‐world data. Hematological oncology. 37 (4), pp. 490-492. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sakellari, I. et al. (2019). Brentuximab vedotin and anti‐PD1 treatment optimize survival in chemo‐refractory Hodgkin lymphoma patients: Real‐world data. Hematological oncology. 37 (4), pp. 490-492. [Online].